Signet Investment Advisory Group Inc. Sells 58 Shares of Johnson & Johnson (NYSE:JNJ)

Signet Investment Advisory Group Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.2% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 24,307 shares of the company’s stock after selling 58 shares during the period. Johnson & Johnson makes up approximately 2.6% of Signet Investment Advisory Group Inc.’s holdings, making the stock its 8th largest holding. Signet Investment Advisory Group Inc.’s holdings in Johnson & Johnson were worth $4,308,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Patron Partners LLC raised its position in shares of Johnson & Johnson by 12.7% in the 1st quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock valued at $1,174,000 after purchasing an additional 747 shares in the last quarter. Tandem Investment Advisors Inc. raised its position in shares of Johnson & Johnson by 4.8% in the 1st quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after purchasing an additional 15,003 shares in the last quarter. Argent Advisors Inc. raised its position in shares of Johnson & Johnson by 6.6% in the 1st quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock valued at $3,504,000 after purchasing an additional 1,218 shares in the last quarter. Exeter Financial LLC raised its position in shares of Johnson & Johnson by 3.2% in the 1st quarter. Exeter Financial LLC now owns 26,431 shares of the company’s stock valued at $4,684,000 after purchasing an additional 819 shares in the last quarter. Finally, Fusion Capital LLC raised its position in shares of Johnson & Johnson by 7.8% in the 1st quarter. Fusion Capital LLC now owns 27,844 shares of the company’s stock valued at $4,935,000 after purchasing an additional 2,019 shares in the last quarter. 68.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Raymond James boosted their price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating for the company. Credit Suisse Group boosted their price target on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. UBS Group lowered their price target on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $189.89.

Insider Activity

In other news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Trading Down 0.6 %

Shares of JNJ stock opened at $172.92 on Wednesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The stock has a fifty day moving average of $175.67 and a two-hundred day moving average of $174.49. The firm has a market capitalization of $455.02 billion, a PE ratio of 25.17, a price-to-earnings-growth ratio of 3.32 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The company had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. During the same quarter in the previous year, the firm posted $2.48 EPS. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. As a group, research analysts expect that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a dividend yield of 2.61%. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.